Independent evidence resource
Guides, comparisons, and research summaries for grading what is known, what remains investigational, and what a study can—and cannot—show about ibogaine efficacy.
Steady Lantern 51 is built for careful context, not treatment recommendations.
What these services are for
The service is interpretation: placing research design, outcome measures, limitations, and safety context beside the claim being made.
Our evidence-focused starting point is intended for people seeking careful, accessible context on ibogaine research, including patients, families, and policy-minded professionals. It does not replace individualized medical care, screening, or emergency guidance.
Ibogaine remains a drug of concern from both an efficacy and safety perspective; the FDA warning on ibogaine for opioid withdrawal underscores why evidence conversations must include serious risks and not only reported benefits.
Information offerings
Each offering is an information service. It organizes available material in plain language and keeps distinctions visible between early findings, observed associations, and established treatment claims.
Structured guides explain why study design, sample size, follow-up, comparison groups, and outcomes matter when weighing an efficacy claim. The evidence grade framework makes the hierarchy of evidence easier to inspect without overstating certainty.
Research summaries distinguish case reports, observational work, and controlled studies so that the method is not mistaken for proof. Our study-method explanations focus on what a design can support and where uncertainty remains.
Questions about use vary substantially by context. Background on ibogaine for opioid addiction can be read alongside material on ibogaine and PTSD, without treating either topic as a settled indication.
Plain-language definitions and the evidence FAQ collection help readers identify common terms, recurring questions, and limits in the available record. The approach reflects the purpose and independence of Steady Lantern 51.
Research summaries
Summaries are designed to make the conditions around a result visible: who was studied, what was measured, how long outcomes were followed, and whether a comparison group was used. Those details shape how far a conclusion can reasonably travel.
They also place ibogaine in a broader research vocabulary. The basic evidence-based medicine framework recognizes that evidence quality, clinical expertise, and individual circumstances are distinct considerations; an information resource should not collapse them into one promise.
“A promising observation and an established treatment claim are not interchangeable.”
Decision context
Readers may encounter differing descriptions of access, setting, tradition, and legal status. Our resources place these differences in context, from ibogaine information in the United States to background on treatment questions in Oregon and the wider map of ibogaine treatment locations.
Historical and cultural context also deserves precision. Discussion of ibogaine and Bwiti should not be used to convert cultural reference into a safety or efficacy claim. The National Institute on Drug Abuse overview of drugs and brain health provides a useful reminder that psychoactive substances can carry varied and serious effects.
Evidence first
Use the evidence guide to orient a claim before relying on it for a high-stakes decision.